The Consortium is a multidisciplinary, collaborative working group that includes researchers at the University of Pennsylvania, Grenoble University in France, Landspitali University Hospital in Iceland, Ohio State University, Charité University Hospital in Berlin, Ohio State University, University of Western Australia, the University of Sydney, Chang Gung Memorial Hospital, and Médicado Instituto do Sono. We work closely with sleep physicians and clinical researchers in affiliated institutions.
The Consortium aims to establish an international clinical and epidemiological database resource and linked biospecimen resource (DNA plus sera) in order to investigate the genetic causes of sleep apnea. As part of this consortium, questionnaire data, sleep-associated data and blood samples will be linked (with informed consent) from patients diagnosed with sleep apnea for the purposes of investigating the genetics of sleep apnea and the genetic risk factors for the various co-morbidities.
By collecting a large range of information about study participants, we hope to gain a comprehensive understanding of the genetic factors associated with sleep apnea and its co-morbidities in order to better manage, treat and prevent the disorder.
1. To establish a large international biospecimen resource (including DNA and sera) from consented sleep apnea patients.
2. To investigate the genetics and genomics of sleep apnea and the complex interplays with other diseases and disorders, including cardiovascular and metabolic co-morbidities.
3. To investigate better phenotyping of sleep apnea, in particular utilizing craniofacial and morphometric measures.
4. To establish standardized instruments for use in genetic studies of sleep apnea to allow better comparability between studies.